Somasundar Prasad Gabbita
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$3.1MFederal grants as PI7 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
7 awards · $3.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 23, 2022 | NIH | SBIR Phase II A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD | $374K | P2D, INC |
| Sep 16, 2021 | NIH | SBIR Phase II A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD | $470K | P2D, INC |
| Aug 20, 2020 | NIH | SBIR Phase I Targeting Latexin for radiation mitigation. | $284K | P2D, INC |
| Jul 17, 2019 | NIH | SBIR Phase II A first-in-class orally active anti-TNF-alpha inhibitor to treat AD | $167K | P2D, INC |
| Sep 14, 2018 | NIH | SBIR Phase II A first-in-class orally active anti-TNF-alpha inhibitor to treat AD | $338K | P2D, INC |
| May 26, 2016 | NIH | SBIR Phase II A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment. | $745K | P2D, INC |
| Aug 31, 2015 | NIH | SBIR Phase II A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment. | $745K | P2D, INC |
1 patents as inventor
- US P2D, INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#575
Awards as PI#250
Patents#273
Companies
- P2D, INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.